Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation…
Galeries Lafayette to open doors in India with Aditya Birla Group early next month
The debut flagship in Mumbai's Kala Ghoda district will bring global fashion,…
AAF Management Closes $55M for Early Stage Hybrid Fund
Washington, D.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Venture capital firm AAF…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
LANZAJET – AN EARLY MOVER IN AUSTRALIA – APPLAUDS THE AUSTRALIAN GOVERNMENT’S LEADERSHIP AND GAME-CHANGING $1.1B (AUD) INVESTMENT TO ADVANCE SUSTAINABLE FUELS
LanzaJet's Alcohol-to-Jet technology for sustainable fuel production is key to enabling the…
The Aleo Network Foundation Joins Binance Alpha, Expanding Early Access to Privacy-First Blockchain
Binance Alpha Pre-Listing Program Makes the ALEO Token Accessible to Millions of…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
How Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early Investors
VALLETTA, Malta, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sparkvia AI has officially…
Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps…
